The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation
Conditions: Langerhans Cell Histiocytosis; Erdheim-Chester Disease; LCH; ECD Intervention: Drug: HLX208 Sponsor: Shanghai Henlius Biotech Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials